Despite a few FDA qualms, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) embraced a fixed combination diabetes drug that couples a titratable basal insulin product with a glucagon-like peptide-1 (GLP-1) receptor agonist that has only a few recommended effective doses.